Company Profile
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China.
The company's core product is EAL, a multi-target cellular immunotherapy product that has completed Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer.
It also develops CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia that is in Phase II/III clinical trial. Its portfolio also includes 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer, RC19D2 for relapsed and refractory diffuse large B-cell lymphoma that is in Phase I clinical trial, and TCR-T cell series products to treat solid tumors.
Additionally, it develops pre-clinical products, such as aT19 to treat hematologic malignancies. Its portfolio also includes YT003 and YT008 for post transplantation infections, YT007 for solid tumors, and VAC-aT19 for hematologic malignancies. Founded in 2006, Immunotech Biopharm is headquartered in Beijing, the People's Republic of China.